Current status of neuroprotection for cerebral ischemia synoptic overview

Research output: Contribution to journalArticle

188 Citations (Scopus)

Abstract

Abundant preclinical studies have identified multiple mechanisms of ischemic brain injury and have provided proof of principle that strategies designed to counter these mechanisms can protect the ischemic brain. This review article emphasizes the translation of these strategies from the laboratory to clinical trials. It is a disappointing fact that many agents have been brought to clinical trial despite only modest or inconsistent preclinical evidence of neuroprotective efficacy. Preclinical investigations require rigorous attention to a variety of variables that may influence outcome. The widely touted STAIR criteria represent constructive guidelines for preclinical testing but, as experience has shown, do not increase the likelihood of translational success. Of the ≈160 clinical trials of neuroprotection for ischemic stroke conducted as of late 2007, only ≈40 represent larger-phase completed trials, and fully one half of the latter utilized a window to treatment of >6 hours, despite strong preclinical evidence that this delay exceeds the likely therapeutic window of efficacy in acute stroke. Other shortcomings of these trials include the use of agents lacking robust, consistent preclinical efficacy; inability to achieve adequate dosing in humans; and suboptimal clinical and statistical design features. Taken together, these factors identify areas of needed improvement for future trials.

Original languageEnglish
JournalStroke
Volume40
Issue number3 SUPPL. 1
DOIs
StatePublished - Mar 1 2009

Fingerprint

Brain Ischemia
Clinical Trials
Stroke
Brain Injuries
Guidelines
Brain
Neuroprotection
Therapeutics

Keywords

  • Infarction
  • Ischemia
  • Neuroprotection
  • Stroke
  • Therapeutic window

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialized Nursing

Cite this

Current status of neuroprotection for cerebral ischemia synoptic overview. / Ginsberg, Myron.

In: Stroke, Vol. 40, No. 3 SUPPL. 1, 01.03.2009.

Research output: Contribution to journalArticle

@article{d790a8b5db424a6a9161c757fe011f8e,
title = "Current status of neuroprotection for cerebral ischemia synoptic overview",
abstract = "Abundant preclinical studies have identified multiple mechanisms of ischemic brain injury and have provided proof of principle that strategies designed to counter these mechanisms can protect the ischemic brain. This review article emphasizes the translation of these strategies from the laboratory to clinical trials. It is a disappointing fact that many agents have been brought to clinical trial despite only modest or inconsistent preclinical evidence of neuroprotective efficacy. Preclinical investigations require rigorous attention to a variety of variables that may influence outcome. The widely touted STAIR criteria represent constructive guidelines for preclinical testing but, as experience has shown, do not increase the likelihood of translational success. Of the ≈160 clinical trials of neuroprotection for ischemic stroke conducted as of late 2007, only ≈40 represent larger-phase completed trials, and fully one half of the latter utilized a window to treatment of >6 hours, despite strong preclinical evidence that this delay exceeds the likely therapeutic window of efficacy in acute stroke. Other shortcomings of these trials include the use of agents lacking robust, consistent preclinical efficacy; inability to achieve adequate dosing in humans; and suboptimal clinical and statistical design features. Taken together, these factors identify areas of needed improvement for future trials.",
keywords = "Infarction, Ischemia, Neuroprotection, Stroke, Therapeutic window",
author = "Myron Ginsberg",
year = "2009",
month = "3",
day = "1",
doi = "10.1161/STROKEAHA.108.528877",
language = "English",
volume = "40",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "3 SUPPL. 1",

}

TY - JOUR

T1 - Current status of neuroprotection for cerebral ischemia synoptic overview

AU - Ginsberg, Myron

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Abundant preclinical studies have identified multiple mechanisms of ischemic brain injury and have provided proof of principle that strategies designed to counter these mechanisms can protect the ischemic brain. This review article emphasizes the translation of these strategies from the laboratory to clinical trials. It is a disappointing fact that many agents have been brought to clinical trial despite only modest or inconsistent preclinical evidence of neuroprotective efficacy. Preclinical investigations require rigorous attention to a variety of variables that may influence outcome. The widely touted STAIR criteria represent constructive guidelines for preclinical testing but, as experience has shown, do not increase the likelihood of translational success. Of the ≈160 clinical trials of neuroprotection for ischemic stroke conducted as of late 2007, only ≈40 represent larger-phase completed trials, and fully one half of the latter utilized a window to treatment of >6 hours, despite strong preclinical evidence that this delay exceeds the likely therapeutic window of efficacy in acute stroke. Other shortcomings of these trials include the use of agents lacking robust, consistent preclinical efficacy; inability to achieve adequate dosing in humans; and suboptimal clinical and statistical design features. Taken together, these factors identify areas of needed improvement for future trials.

AB - Abundant preclinical studies have identified multiple mechanisms of ischemic brain injury and have provided proof of principle that strategies designed to counter these mechanisms can protect the ischemic brain. This review article emphasizes the translation of these strategies from the laboratory to clinical trials. It is a disappointing fact that many agents have been brought to clinical trial despite only modest or inconsistent preclinical evidence of neuroprotective efficacy. Preclinical investigations require rigorous attention to a variety of variables that may influence outcome. The widely touted STAIR criteria represent constructive guidelines for preclinical testing but, as experience has shown, do not increase the likelihood of translational success. Of the ≈160 clinical trials of neuroprotection for ischemic stroke conducted as of late 2007, only ≈40 represent larger-phase completed trials, and fully one half of the latter utilized a window to treatment of >6 hours, despite strong preclinical evidence that this delay exceeds the likely therapeutic window of efficacy in acute stroke. Other shortcomings of these trials include the use of agents lacking robust, consistent preclinical efficacy; inability to achieve adequate dosing in humans; and suboptimal clinical and statistical design features. Taken together, these factors identify areas of needed improvement for future trials.

KW - Infarction

KW - Ischemia

KW - Neuroprotection

KW - Stroke

KW - Therapeutic window

UR - http://www.scopus.com/inward/record.url?scp=62949204563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62949204563&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.108.528877

DO - 10.1161/STROKEAHA.108.528877

M3 - Article

C2 - 19064810

AN - SCOPUS:62949204563

VL - 40

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 3 SUPPL. 1

ER -